These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22406455)

  • 1. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil.
    Mahoney RT; Francis DP; Frazatti-Gallina NM; Precioso AR; Raw I; Watler P; Whitehead P; Whitehead SS
    Vaccine; 2012 Jul; 30(32):4892-6. PubMed ID: 22406455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.
    Precioso AR; Palacios R; Thomé B; Mondini G; Braga P; Kalil J
    Vaccine; 2015 Dec; 33(50):7121-5. PubMed ID: 26458796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.
    Durbin AP
    Curr Opin Virol; 2020 Aug; 43():79-87. PubMed ID: 33164790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in reducing dengue burden; diagnostics, control measures and vaccines.
    Lam SK
    Expert Rev Vaccines; 2013 Sep; 12(9):995-1010. PubMed ID: 24053394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current issues in the economics of vaccination against dengue.
    Tozan Y
    Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review.
    Endo IC; Ziegelmann PK; Patel A
    Vaccine; 2016 Dec; 34(50):6133-6147. PubMed ID: 27810313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Future prospects in developing of dengue vaccines].
    Valero N; Levy A
    Invest Clin; 2008 Jun; 49(2):135-8. PubMed ID: 18717261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
    Lee HC; Butler M; Wu SC
    Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
    Flasche S; Jit M; Rodríguez-Barraquer I; Coudeville L; Recker M; Koelle K; Milne G; Hladish TJ; Perkins TA; Cummings DA; Dorigatti I; Laydon DJ; España G; Kelso J; Longini I; Lourenco J; Pearson CA; Reiner RC; Mier-Y-Terán-Romero L; Vannice K; Ferguson N
    PLoS Med; 2016 Nov; 13(11):e1002181. PubMed ID: 27898668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating potential demand and supply of dengue vaccine in Brazil.
    Amarasinghe A; Mahoney RT
    Hum Vaccin; 2011 Jul; 7(7):776-80. PubMed ID: 21734468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland.
    Cassetti MC; Halstead SB
    Vaccine; 2014 May; 32(26):3115-21. PubMed ID: 24768502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
    Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
    Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.